The Patent Trial and Appeal Board (PTAB) has invalidated claims in two Teva-owned patents covering Copaxone (glatiramer acetate injection), prompting the Israel-based company to announce its intention to appeal against the ruling.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
PTAB, Teva, Copaxone, patents, ANDA